找回密码
 立即注册

微信扫码登录

搜索

[不可手术无驱动] 不可切除局部晚期非小细胞肺癌姑息性放疗:即刻还是延迟?

[复制链接]
杨学宁医师 发表于 2023-5-7 15:59:33 | 显示全部楼层 |阅读模式
Falk SJ, Girling DJ, White RJ, Hopwood P, Harvey A, Qian W, Stephens RJ; Medical Research Council Lung Cancer Working Party. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ. 2002 Aug 31;325(7362):465. doi: 10.1136/bmj.325.7362.465. PMID: 12202326; PMCID: PMC119441.
Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial - PMC (nih.gov)

Objective: To determine whether patients with locally advanced non-small cell lung cancer unsuitable for resection or radical radiotherapy, and with minimal thoracic symptoms, should be given palliative thoracic radiotherapy immediately or as needed to treat symptoms.
Design: Multicentre randomised controlled trial.
Setting: 23 centres in the United Kingdom, Ireland, and South Africa.
Participants: 230 patients with previously untreated, non-small cell lung cancer that is locally too advanced for resection or radical radiotherapy with curative intent, with minimal thoracic symptoms, and with no indication for immediate thoracic radiotherapy.
Interventions: All patients were given supportive treatment and were randomised to receive palliative thoracic radiotherapy either immediately or delayed until needed to treat symptoms. The recommended regimens were 17 Gy in two fractions one week apart or 10 Gy as a single dose.
Main outcome measures: Primary--patients alive and without moderate or severe cough, chest pain, haemoptysis, or dyspnoea six months from randomisation, as recorded by clinicians. Secondary--quality of life, adverse events, survival.
Results: From December 1992 to May 1999, 230 patients were randomised. 104/115 of the patients in the immediate treatment group received thoracic radiotherapy (90 received one of the recommended regimens). In the delayed treatment group, 48/115 (42%) patients received thoracic radiotherapy (29 received one of the recommended regimens); 64 (56%) died without receiving thoracic radiotherapy; the remaining three (3%) were alive at the end of the study without having received the treatment. For patients who received thoracic radiotherapy, the median time to start was 15 days in the immediate treatment group and 125 days in the delayed treatment group. The primary outcome measure was achieved in 28% of the immediate treatment group and 26% of patients from the delayed treatment group (27/97 and 27/103, respectively; absolute difference 1.6%, 95% confidence interval -10.7% to 13.9%). No evidence of a difference was observed between the two treatment groups in terms of activity level, anxiety, depression, and psychological distress, as recorded by the patients. Adverse events were more common in the immediate treatment group. Neither group had a survival advantage (hazard ratio 0.95, 0.73 to 1.24; P=0.71). Median survival was 8.3 months and 7.9 months, and the survival rates were 31% and 29% at 12 months, for the immediate and delayed treatment groups, respectively.
Conclusion: In minimally symptomatic patients with locally advanced non-small cell lung cancer, no persuasive evidence was found to indicate that giving immediate palliative thoracic radiotherapy improves symptom control, quality of life, or survival when compared with delaying until symptoms require treatment.



Hansen HH. Treatment of advanced non-small cell lung cancer. BMJ. 2002 Aug 31;325(7362):452-3. doi: 10.1136/bmj.325.7362.452. PMID: 12202311; PMCID: PMC1123980.

Treatment of advanced non-small cell lung cancer - PMC (nih.gov)

In spite of a worldwide intensification of the battle against tobacco consumption, the incidence of lung cancer continues to rise in parallel with the increased consumption of tobacco. This is especially so in women in Western countries and in men and women in developing countries.
Major strides have been made in our knowledge of the biology of lung cancer. But we still await the impact of this information on prevention, early diagnosis, and cure rate, which has been essentially unchanged during the past couple of decades, with a five year survival rate for non-small cell lung cancer of 8-14%. The figures vary somewhat from country to country, with almost half the patients dying within the first year of diagnosis in spite of the best clinical treatments.1
Non-small cell lung cancer includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. It accounts for 75-80% of all new patients; the remaining are small cell carcinomas. Of all patients with newly diagnosed non-small cell lung cancer, 70-75% have locoregional or advanced, unresectable disease. Recent large studies and meta-analyses have clearly shown the benefit of combined modality treatment (chemotherapy with or without surgery with or without radiotherapy) with improvements in median and two year survival for patients with locoregional disease, while the treatment of advanced disease is still being debated.2,3
Until the late 1990s, the most commonly accepted symptomatic treatment consisted of palliative radiotherapy. A recent Cochrane review of 10 randomised trials using varying doses of radiotherapy concluded that there is no strong evidence that any regimen gives superior palliation.4 A recent British study with 148 patients challenges this conclusion by showing that fractionated thoracic irradiation (30 Gy in 10 daily fractions) afforded better relief of symptoms and reduced anxiety compared with single fractions (10 Gy), but did not increase survival.5 According to the Cochrane review, there is evidence for a modest increase in survival (6% at one year and 3% at two years) in patients with good performance status given higher doses of radiotherapy.
With palliation as the aim, most patients should be treated with short courses of one or two fractions—as in the study in this issue by the Medical Research Council's lung cancer working party—using either 17 Gy as two 8.5 Gy fractions one week apart or less frequently 10 Gy as a single dose, based on two previous MRC trials (p 465).6 Patients were randomised with a reasonable stratification to supportive treatment plus either immediate or delayed thoracic radiotherapy. The study included 230 patients with non-small cell lung cancer that was locally too advanced for surgical resection or intensive radiotherapy with curative intent. Cytostatic chemotherapy was not permissible in any group. The median time to start of thoracic radiotherapy was 15 days in the intermediate group and 125 days in the delayed group. No differences were noted in primary study measures such as percentage of patients alive and without moderate or several local symptoms, nor were there any differences in secondary measures, such as quality of life, adverse events, or survival. Interestingly, 58% of the patients in the delayed group did not receive thoracic radiotherapy at all, thus reserving the much needed capacity of oncology centres for other patients in need of irradiation.
This study took place over a six year period in the mid-1990s. In the meantime evidence has emerged, based on meta-analysis including Cochrane analyses, that combination chemotherapy with cisplatin in a similar group of patients results in improvement in one year survival by 10% provided that the patients had a good performance status at the time of diagnosis.7,8 Symptomatic improvement is reported in 60% of all such patients. Further, patients with progressive disease during chemotherapy have been shown in two recent randomised studies to benefit from single agent chemotherapy, based on both survival and control of symptoms.9,10
The picture has thus changed since the conclusion of the trial reported in this issue leaving a number of questions open for future studies. These include a clarification of whether or not delayed chemotherapy is as effective as immediate chemotherapy for certain selected groups of patients, as shown for radiotherapy in this study,6 or whether the two modalities should be combined and administered at the time of diagnosis.
Considering the large number of patients and the implications for resources available in the healthcare system, carefully planned multinational studies are needed, including socioeconomic analyses, as well as prospective trials including patients with poor performance status.11 Until results from such studies become available, the management of patients with advanced non-small cell lung cancer should be discussed carefully with patients and relatives, and detailed information should be given regarding the benefits and harms associated with the treatment and the timing of it.
本帖共 1 条回复,登录后VIP可查看

给我们建议|手机版|阳光肺科 ( 粤ICP备2020077405号-1 )

GMT+8, 2026-11-23 00:12

Powered by Discuz! X3.5

© 2001-2026 Discuz! Team.

快速回复 返回顶部 返回列表